Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alcon AG (ALC) vs Oklo Inc (OKLO) Price & Performance

Price performance (Past 24H)

Key statistics

Alcon AG vs Oklo Inc — how do they compare? Alcon AG trades at $73.73 (market cap $36.44B), while Oklo Inc trades at $45.32 (market cap $8.74B). The key difference: Alcon AG is far larger — about 4.2× Oklo Inc's market cap, and Alcon AG pays a 0.48% dividend while Oklo Inc pays none. Which is the better fit depends on your goals.

ALCOKLO
Market Cap
$36.44B$8.74B
Sector
HealthTechnology
52-Week High
$90.12$174.14
52-Week Low
$62.02$36.84
Enterprise Value
$40.28B$6.28B
Dividend Yield
0.48%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alcon AG

ALC trades at $73.525, down 0.14% on the day, with a bullish technical signal from moving averages and positive analyst sentiment. Recent Q2 2026 earnings beat estimates, with revenue of $10.4 billion in 2025 and a net income margin of 5.92%. The company raised its 2026 profitability outlook, citing tariff relief and strong product launches.

The stock offers a 17.9% upside to the consensus price target of $86.67, supported by bullish analyst ratings and improving cash flow trends. Key risks include elevated P/E valuation at 57.52 and potential macroeconomic pressures on medical device demand. Earnings growth and execution on new products remain critical for sustained momentum.

Oklo Inc

OKLO trades at $45.71, up 2.74% with a bullish technical outlook despite recent volatility. The company reported its first revenue of $1.2 million in Q2 2026 but continues to post significant losses (-$105.66M net income in 2025) with negative margins. Analyst consensus remains strongly bullish with a $77.07 price target, though CEO share sales and high cash burn present near-term concerns.

While OKLO shows promising nuclear technology development with recent milestones, investors face substantial execution risks amid widening losses and negative cash flow. The stock offers high growth potential in the emerging nuclear energy sector but requires careful risk management given the pre-profitability stage and volatile price action.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alcon AG

Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.

Read more on ALC

About Oklo Inc

Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.

Read more on OKLO